Consensus Update for Systemic Treatment of Atopic Dermatitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ji Hyun | - |
dc.contributor.author | Kim, Jung Eun | - |
dc.contributor.author | Park, Gyeong-Hun | - |
dc.contributor.author | Bae, Jung Min | - |
dc.contributor.author | Byun, Ji Yeon | - |
dc.contributor.author | Shin, Min Kyung | - |
dc.contributor.author | Han, Tae Young | - |
dc.contributor.author | Hong, Seung Phil | - |
dc.contributor.author | Jang, Yong Hyun | - |
dc.contributor.author | Kim, Hye One | - |
dc.contributor.author | Na, Chan Ho | - |
dc.contributor.author | Lew, Bark-Lynn | - |
dc.contributor.author | Ahn, JiYoung | - |
dc.contributor.author | Park, Chang Ook | - |
dc.contributor.author | Seo, Young-Joon | - |
dc.contributor.author | Lee, Yang Won | - |
dc.contributor.author | Son, Sang Wook | - |
dc.contributor.author | Choi, Eung Ho | - |
dc.contributor.author | Park, Young Lip | - |
dc.contributor.author | Roh, Joo Young | - |
dc.date.accessioned | 2022-11-04T03:42:08Z | - |
dc.date.available | 2022-11-04T03:42:08Z | - |
dc.date.created | 2022-11-04 | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 1013-9087 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/144608 | - |
dc.description.abstract | Background: In 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD). Objective: We aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience. Methods: We compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recom-mendations. Results: We do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not rec-ommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treat-ment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate. Conclusion: We look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN DERMATOLOGICAL ASSOC | - |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject | VITAMIN-D SUPPLEMENTATION | - |
dc.subject | EVENING PRIMROSE OIL | - |
dc.subject | LONG-TERM TREATMENT | - |
dc.subject | STAPHYLOCOCCUS-AUREUS COLONIZATION | - |
dc.subject | ALLERGEN-SPECIFIC IMMUNOTHERAPY | - |
dc.subject | MITE-SENSITIZED CHILDREN | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | HISTAMINE H-4 RECEPTOR | - |
dc.subject | DOUBLE-BLIND | - |
dc.title | Consensus Update for Systemic Treatment of Atopic Dermatitis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Son, Sang Wook | - |
dc.identifier.doi | 10.5021/ad.2021.33.6.497 | - |
dc.identifier.scopusid | 2-s2.0-85119609554 | - |
dc.identifier.wosid | 000718138800002 | - |
dc.identifier.bibliographicCitation | ANNALS OF DERMATOLOGY, v.33, no.6, pp.497 - 514 | - |
dc.relation.isPartOf | ANNALS OF DERMATOLOGY | - |
dc.citation.title | ANNALS OF DERMATOLOGY | - |
dc.citation.volume | 33 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 497 | - |
dc.citation.endPage | 514 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002781050 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | VITAMIN-D SUPPLEMENTATION | - |
dc.subject.keywordPlus | EVENING PRIMROSE OIL | - |
dc.subject.keywordPlus | LONG-TERM TREATMENT | - |
dc.subject.keywordPlus | STAPHYLOCOCCUS-AUREUS COLONIZATION | - |
dc.subject.keywordPlus | ALLERGEN-SPECIFIC IMMUNOTHERAPY | - |
dc.subject.keywordPlus | MITE-SENSITIZED CHILDREN | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | HISTAMINE H-4 RECEPTOR | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordAuthor | Atopic dermatitis | - |
dc.subject.keywordAuthor | Consensus | - |
dc.subject.keywordAuthor | Republic of Korea | - |
dc.subject.keywordAuthor | Systemic treatment | - |
dc.subject.keywordAuthor | Therapeu-tics | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.